Ann: Retina Target Engagement Confirmed in Large Eye, page-7

We are rapidly derisking on our way to be ready for entering the clinic mid next year.
The fair value then is about 40 to 50 cents, especially since US investors will follow the funding arranged overseas, which I expect to be staggered with an advanced pay, staggered pays on milestones achievements financing the CNS pipelines with money unimaginable currently by market.
CEO was mentioning triple the current market cap ( they really are giving shareholders ample hints what to expect ), which would translate on funding news,
anytime from now to early next year.
Add to the mix that gene therapy and AAV approach is witnessing strong setbacks and clearing the way for more
attention to our

Lots of catching up to do by market, so this is one rare undervalued opportunity on the ASX in an otherwise overpriced market.

all IMO